Skip to main content
Top
Published in: BMC Public Health 1/2019

Open Access 01-12-2019 | Multiple Sclerosis | Research article

Economic burden of multiple sclerosis in a population with low physical disability

Authors: José M. García-Domínguez, Jorge Maurino, María L. Martínez-Ginés, Olga Carmona, Ana B. Caminero, Nicolás Medrano, Elena Ruíz-Beato, for the W-IMPACT Clinical Investigators

Published in: BMC Public Health | Issue 1/2019

Login to get access

Abstract

Background

In multiple sclerosis (MS), half of affected people are unemployed within 10 years of diagnosis. The aim of this study was to assess the economic impact of MS in adult subjects with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS).

Methods

A multicenter, non-interventional, cross-sectional study was conducted. The Expanded Disability Status Scale (EDSS) and the 23-item Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ-23) were used to assess disability and work performance, respectively. Only indirect costs were considered using the human capital method, including work costs. Professional support costs and informal caregivers’ costs were also estimated.

Results

A total of 199 subjects were studied (mean age: 43.9 ± 10.5 years, 60.8% female, 86.4% with RRMS). Median EDSS score was 2.0 (interquartile range: 1.0–3.5) and median MSWDQ-23 total score was 31.5 (15.2, 50.0). The number of employed subjects decreased after MS diagnosis from 70.6 to 47.2%, and the number of retired people increased (23.6%). Mean age of retirement was 43.6 ± 10.5 years. Ten percent of the population had sick leaves (absenteeism was seen in 90.9% of the student population and 30.9% of the employed population). Professional support in their daily life activities was needed in 28.1% of subjects. Costs for sick leave, work absenteeism, premature retirement and premature work disability/pensioner were €416.6 ± 2030.2, €763.4 ± 3161.8, €5810.1 ± 13,159.0 and €1816.8 ± 9630.7, respectively. Costs for professional support and informal caregiving activities were €1026.93 ± 4622.0 and €1328.72, respectively.

Conclusions

MS is responsible for a substantial economic burden due to indirect and informal care costs, even in a population with low physical disability.
Literature
1.
go back to reference Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123–36.CrossRef Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123–36.CrossRef
2.
go back to reference Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis - a systematic review. PLoS One. 2016;11:e0159129.CrossRef Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis - a systematic review. PLoS One. 2016;11:e0159129.CrossRef
3.
go back to reference Tinelli M, Kanavos P, Efthymiadou O, et al. Using IMPrESS to guide policy change in multiple sclerosis. Mult Scler. 2018;24:1251–5.CrossRef Tinelli M, Kanavos P, Efthymiadou O, et al. Using IMPrESS to guide policy change in multiple sclerosis. Mult Scler. 2018;24:1251–5.CrossRef
4.
5.
go back to reference Uccelli MM. The impact of multiple sclerosis on family members: a review of the literature. Neurodegener Dis Manag. 2014;4:177–85.CrossRef Uccelli MM. The impact of multiple sclerosis on family members: a review of the literature. Neurodegener Dis Manag. 2014;4:177–85.CrossRef
6.
go back to reference Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34:919–39.CrossRef Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34:919–39.CrossRef
8.
go back to reference Fernández O, Calleja-Hernández MA, Meca-Lallana J, et al. Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Rev Pharmacoecon Outcomes Res. 2017;17:321–33.CrossRef Fernández O, Calleja-Hernández MA, Meca-Lallana J, et al. Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Rev Pharmacoecon Outcomes Res. 2017;17:321–33.CrossRef
9.
go back to reference Sicras-Mainar A, Ruíz-Beato E, Navarro-Artieda R, et al. Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Serv Res. 2017;17:854.CrossRef Sicras-Mainar A, Ruíz-Beato E, Navarro-Artieda R, et al. Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Serv Res. 2017;17:854.CrossRef
10.
go back to reference Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.CrossRef Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.CrossRef
11.
go back to reference Martínez-Ginés ML, García-Domínguez JM, Forero L, et al. Spanish validation of a specific measure to assess work-related problems in people with multiple sclerosis: the multiple sclerosis work difficulties questionnaire (MSWDQ-23). Mult Scler Relat Disord. 2018;22:115–9.CrossRef Martínez-Ginés ML, García-Domínguez JM, Forero L, et al. Spanish validation of a specific measure to assess work-related problems in people with multiple sclerosis: the multiple sclerosis work difficulties questionnaire (MSWDQ-23). Mult Scler Relat Disord. 2018;22:115–9.CrossRef
12.
go back to reference Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.CrossRef Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.CrossRef
13.
go back to reference Hobart J, Lamping D, Fitzpatrick R, et al. The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure. Brain J Neurol. 2001;124:962–73.CrossRef Hobart J, Lamping D, Fitzpatrick R, et al. The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure. Brain J Neurol. 2001;124:962–73.CrossRef
14.
go back to reference Honan CA, Brown RF, Hine DW, et al. The multiple sclerosis work difficulties questionnaire (MSWDQ): development of a shortened scale. Disabil Rehabil. 2014;6:635–41.CrossRef Honan CA, Brown RF, Hine DW, et al. The multiple sclerosis work difficulties questionnaire (MSWDQ): development of a shortened scale. Disabil Rehabil. 2014;6:635–41.CrossRef
15.
go back to reference García-Domínguez JM, Martínez-Ginés ML, Carmona O, et al. Measuring burden in caregivers of people with multiple sclerosis: psychometric properties of the CSI questionnaire. Patient Prefer Adherence. 2019;13:101–6.CrossRef García-Domínguez JM, Martínez-Ginés ML, Carmona O, et al. Measuring burden in caregivers of people with multiple sclerosis: psychometric properties of the CSI questionnaire. Patient Prefer Adherence. 2019;13:101–6.CrossRef
17.
go back to reference Giovannoni G. Can we afford not to prevent MS-related disability? Mult Scler. 2017;23:1048–9.CrossRef Giovannoni G. Can we afford not to prevent MS-related disability? Mult Scler. 2017;23:1048–9.CrossRef
18.
go back to reference Raggi A, Covelli V, Schiavolin S, et al. Work-related problems in multiple sclerosis: a literature review on its associates and determinants. Disabil Rehabil. 2016;38:936–44.CrossRef Raggi A, Covelli V, Schiavolin S, et al. Work-related problems in multiple sclerosis: a literature review on its associates and determinants. Disabil Rehabil. 2016;38:936–44.CrossRef
19.
go back to reference Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ. 2006;7 (Suppl. 2:S65–4.CrossRef Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ. 2006;7 (Suppl. 2:S65–4.CrossRef
20.
go back to reference Karampampa K, Gustavsson A, Miltenburger C, Mora S, Arbizu T. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler. 2012;18:35–9.CrossRef Karampampa K, Gustavsson A, Miltenburger C, Mora S, Arbizu T. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler. 2012;18:35–9.CrossRef
21.
go back to reference Sobocki P, Pugliatti M, Lauer K, et al. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler. 2007;13:1054–64.CrossRef Sobocki P, Pugliatti M, Lauer K, et al. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler. 2007;13:1054–64.CrossRef
22.
go back to reference Parés-Badell O, Barbaglia G, Jerinic P, et al. Cost of disorders of the brain in Spain. PLoS One. 2014;9:e105471.CrossRef Parés-Badell O, Barbaglia G, Jerinic P, et al. Cost of disorders of the brain in Spain. PLoS One. 2014;9:e105471.CrossRef
23.
go back to reference Oreja-Guevara C, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Spain. Mult Scler. 2017;23:166–78.CrossRef Oreja-Guevara C, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Spain. Mult Scler. 2017;23:166–78.CrossRef
24.
go back to reference Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9:S5–S48.CrossRef Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9:S5–S48.CrossRef
25.
go back to reference Cerqueira JJ, Compston DAS, Geraldes R, et al. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? J Neurol Neurosurg Psychiatry. 2018;89:844–50.CrossRef Cerqueira JJ, Compston DAS, Geraldes R, et al. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? J Neurol Neurosurg Psychiatry. 2018;89:844–50.CrossRef
26.
go back to reference Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263:1053–65.CrossRef Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263:1053–65.CrossRef
27.
go back to reference Chen J, Taylor BV, Blizzard L, et al. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. J Neurol Neurosurg Psychiatry. 2018;89:1200–7.CrossRef Chen J, Taylor BV, Blizzard L, et al. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. J Neurol Neurosurg Psychiatry. 2018;89:1200–7.CrossRef
Metadata
Title
Economic burden of multiple sclerosis in a population with low physical disability
Authors
José M. García-Domínguez
Jorge Maurino
María L. Martínez-Ginés
Olga Carmona
Ana B. Caminero
Nicolás Medrano
Elena Ruíz-Beato
for the W-IMPACT Clinical Investigators
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2019
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-019-6907-x

Other articles of this Issue 1/2019

BMC Public Health 1/2019 Go to the issue